|Dr. Garo H. Armen||Co-Founder & Exec. Chairman||N/A||N/A||1953|
|Dr. Alexander Kenneth Arrow C.F.A., M.D., CFA||CFO & Sec.||38.46k||N/A||1971|
|Dr. Andrew Slee||Chief Operating Officer||N/A||N/A||1950|
|Dr. Robert Benjamin Stein||Chief Medical Officer & Director||N/A||N/A||1951|
|Dr. David A. Lovejoy||Chief Scientific Officer, Scientific Founder & Scientific Advisor||N/A||N/A||N/A|
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Protagenic Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.